According to Drucker the findings, published in December 2023, provided the first demonstration of 'a GLP-1-brain-immune axis that controls inflammation across the body independent of weight loss, even in peripheral organs devoid of GLP1 receptors.' Drucker's team has not yet identified which particular brain cells interact with GLP-1 (AAAS)
Heres why patients choose us: Personalized care based on your goals and lab work A full-spectrum approach to mens health and performance Safe, medical-grade peptide protocols overseen by our provider A discreet, professional environment with real results Peptide Therapy FAQS Contact Us Today
The trial was designed as a non-inferiority trial with a pre-specified risk margin of 1.3 for the hazard ratio of MACE, and was also powered for a superiority comparison if non-inferiority was demonstrated
Inflammation in Obesity, Diabetes, and Related Disorders
Lipohypertrophy and Insulin: An Update From the Diabetes Technology Society
